Review of precocious puberty: Part III - Premature thelarche and premature adrenarche. Variations of normal?

Endocrinologist

Volumn 11, Issue 3, 2001, Pages 196-203

  Bauer, Andrew J ^a   Francis, Gary L ^a   Poth, Merrily ^a,b  

^a Uniformed Services University of the Health Sciences   (United States)

^b UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENARCHE; BREAST DEVELOPMENT; DISEASE ASSOCIATION; HEALTH STATUS; HUMAN; PATHOPHYSIOLOGY; PRECOCIOUS PUBERTY; PUBERTY; REVIEW; SEXUAL DEVELOPMENT; SEXUAL MATURATION;

EID: 0034968718     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019616-200105000-00006     Document Type: Review

References (66)

1. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment
2. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatric Research in Office Settings network
3. Current age of onset of puberty
4. Isolated premature thelarche and thelarche variant: Clinical and auxological follow-up of 119 girls
5. A comparison of patients with premature thelarche and idiopathic true precocious puberty in the initial stage of illness
6. Premature thelarche: Natural history and etiologic investigation
7. Natural history of premature thelarche in Olmsted County, Minnesota, 1940 to 1984
8. Normal and almost normal precocious variations in pubertal development premature pubarche and premature thelarche revisited
9. Premature thelarche: A long-term follow-up
10. Premature thelarche and central precocious puberty: The relationship between clinical presentation and the gonadotropin response to luteinizing hormone-releasing hormone
11. Response of plasma LH and FSH to synthetic LH-RH in children at various pubertal stages
12. Thelarche variant: A new syndrome of precocious sexual maturation?
13. The pattern of gonadotropin and estradiol secretion in exaggerated thelarche
14. Progression of premature thelarche to central precocious puberty
15. Studies of gonadotrophin pulsatility and pelvic ultrasound examinations distinguish between isolated premature thelarche and central precocious puberty
16. An epidemic of premature thelarche in Puerto Rico
17. Estrogens from plastic: Are we being exposed?
18. The environmental estrogen bisphenol A stimulates prolactin release in vitro and in vivo
19. Adrenarche: Changing adrenal response to adrenocorticotropin
20. Plasma 17-ketosteroids and 17-beta hydroxysteroids in girls with premature development of sexual hair
21. Isolated precocious pubarche: An approach
22. Follow-up of growth and steroids in premature adrenarche
23. The role of adrenocorticotropin testing in evaluating girls with premature adrenarche and hirsutism/oligomenorrhea
24. Natural history of premature pubarche: An auxological study
25. High frequency of nonclassical steroid 21-hydroxylase deficiency
26. 'Exaggerated adrenarche' in children presenting with premature adrenarche
27. Genetic defects of steroidogenesis in premature pubarche
28. Studies of 3 betahydroxysteroid dehydrogenase genes in infants and children manifesting premature pubarche and increased adrenocorticotropin-stimulated delta 5-steroid levels
29. High incidence of molecular defects of the CYP21 gene in patients with premature adrenarche
30. Postpubertal outcome in girls diagnosed of premature pubarche during childhood: Increased frequency of functional ovarian hyperandrogenism
31. Insulin resistance, premature adrenarche, and a risk of the polycystic ovary syndrome (PCOS)
32. Anovulation after precocious pubarche: Early markers and time course in adolescence
33. Chronic anovulation caused by peripheral endocrine disorders
34. Hyperinsulinemia and decreased insulin-like growth factor-binding protein-1 are common features in prepubertal and pubertal girls with a history of premature pubarche
35. Decreased insulin sensitivity in prepubertal girls with premature adrenarche and acanthosis nigricans
36. The roles of insulin sensitivity, insulin-like growth factor I (IGF-I), and IGF-binding protein-1 and -3 in the hyperandrogenism of African-American and Caribbean-Hispanic girls with premature adrenarche
37. Girls diagnosed with premature pubarche show an exaggerated ovarian androgen synthesis from the early stages of puberty: Evidence from gonadotropin-releasing hormone agonist testing
38. Adrenarche and fetal growth
39. Exaggerated adrenarche and hyperinsulinism in adolescent girls born small for gestational age
40. Insulin resistance in short children with intrauterine growth retardation
41. Insulin resistance in short children with intrauterine growth retardation
42. Precocious pubarche, hyperinsulinism, and ovarian hyperandrogenism in girls: Relation to reduced fetal growth
43. Type 2 (non-insulin-dependent) diabetes mellitus, hypertension and hyperlipidaemia (syndrome X): Relation to reduced fetal growth
44. Birth weight and the insulin resistance syndrome: Association of low birth weight with truncal obesity and raised plasminogen activator inhibitor-1 but not with abdominal obesity or plasma lipid disturbances
45. Corticotropin-releasing hormone as adrenal androgen secretagogue
46. Elevated levels of umbilical cord plasma corticotropin releasing hormone in growth-retarded fetuses
47. Serine phosphorylation of human P450c17 increases 17,20-lyase activity: Implications for adrenarche and the polycystic ovary syndrome
48. The molecular basis of premature adrenarche: An hypothesis
49. Pathophysiology, genetics, and treatment of hyperandrogenism
50. Insulin-like growth factor I and insulin potentiate luteinizing hormone-induced androgen synthesis by rat ovarian thecal-interstitial cells
51. Pronounced adrenarche and precocious pubarche in boys
52. Increased prevalence of type 2 diabetes mellitus and impaired glucose tolerance in first-degree relatives of girls with a history of precocious pubarche
53. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness
54. Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome
55. Current developments in the molecular genetics of the polycystic ovary syndrome
56. Review of precocious puberty part I: Gonadotropin dependent precocious
57. Unsustained or slowly progressive puberty in young girls: Initial presentation and long-term follow-up of 20 untreated patients
58. The modified minimal model: Application to measurement of insulin sensitivity in children
59. Premature adrenarche: Findings in prepubertal African-American and Caribbean-Hispanic girls
60. Treatment of hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism in nonobese, adolescent girls: Effect of flutamide
61. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome
62. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: A randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation
63. Sensitization to insulin in adolescent girls to normalize hirsutism, hyperandrogenism, oligomenorrhea, dyslipidemia, and hyperinsulinism after precocious pubarche
64. Carriers of 21-hydroxylase deficiency are not at increased risk for hyperandrogenism
65. Banting lecture 1988: Role of insulin resistance in human disease
66. Insulin sensitivity, lipids, and body composition in childhood: Is "syndrome X" present?